Research progess in effect of novel coronavirus on cardiovascular system_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LI Lei ¹ , PENG Yixue ¹ , ZHANG Jie ¹ , ZHUO Lijia ¹ , ZHAO Xia ¹ , ZHANG Longhao ² , ZHU Peijia ³ ,  ZENG Guojun ⁴

1. Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Double First-class Construction Office, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
4. Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

ZENG Guojun, Email: benesun@qq.com

Keywords：

SARS-CoV-2; COVID-19; cardiovascular system; review

DOI：

10.7507/1007-4848.202101012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In addition to the typical respiratory symptoms, COVID-19 patients present with clinical manifestations of cardiovascular system damage, and they are at higher risk of intensive care or mortality. The mechanism of COVID-19's impact on the cardiovascular system is still unclear, therefore we need to pay close attention to it. Based on the existing research, this paper focused on the concurrent characteristics of the cardiovascular system diseases, summarized the possible mechanisms of cardiovascular system damage, including the coronavirus invaders directly into cardiomyocytes and its conduction system, with complications or accompanying conditions such as cytokine storm, imbalance of oxygen supply and demand, drug influence, stress and other damage to cardiovascular system. Meanwhile, current clinical manifestations and treatment methods of COVID-19 were summarized.

Citation： LI Lei, PENG Yixue, ZHANG Jie, ZHUO Lijia, ZHAO Xia, ZHANG Longhao, ZHU Peijia, ZENG Guojun. Research progess in effect of novel coronavirus on cardiovascular system. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(1): 106-113. doi: 10.7507/1007-4848.202101012 Copy

1.	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2.	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet, 2020, 395(10224): 565-574.
3.	劉欣, 叢曉東, 李平. 探討新型冠狀病毒對心血管系統的影響. 山東中醫藥大學學報, 2020 , 44(6): 462-546.
4.	World Health Organization. SARS-CoV-2 variant—United Kingdom of Great Britain and Northern Ireland. 2020-12-21.
5.	SARS-CoV-2 variants. World Health Organization. 2020-12-31.
6.	Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13): 1239-1242.
7.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
8.	戴海龍, 馮曉嵐, 周旭, 等. 新型冠狀病毒肺炎對心血管的影響. 心肺血管病雜志, 2021, 39(6): 635-647, 641.
9.	張梅, 李闖. 新型冠狀病毒肺炎與心血管疾病. 武警醫學, 2020, 31(2): 93-96.
10.	倪國華, 李昆, 袁瓊. 新型冠狀病毒肺炎合并心血管疾病患者使用抗病毒藥物的藥學監護. 實用醫學雜志, 2020, 36(6): 3169-3173.
11.	Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5): 531-538.
12.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
13.	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
14.	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.
15.	Li D, Chen Y, Liu H, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: Insights from ERS-COVID-19 study. Signal Transduct Target Ther, 2020, 5(1): 62.
16.	國家衛生健康委辦公廳國家中醫藥管理局辦公室. 關于印發新型冠狀病毒肺炎診療方案(試行第八版)的通知. 江蘇中醫藥, 2020, 52(9): 封2, 前插1-前插4.
17.	Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest, 2009, 39(7): 618-625.
18.	李發久, 朱紫陽, 陳實, 等. 新型冠狀病毒肺炎相關心肌損傷的臨床觀察. 第二軍醫大學學報, 2020, 42(5): 698-703.
19.	姜淑芳, 袁本敏, 韓志武. 新型冠狀病毒感染與心血管疾病. 青島大學學報(醫學版), 2020, 57(1): 156-158.
20.	Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
21.	Guo J, Huang Z, Lin L, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc, 2020, 9(7): e016219.
22.	Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol, 2020, 75(18): 2352-2371.
23.	Prasad A, Panhwar S, Hendel RC, et al. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J, 2020, 226: 174-187.
24.	Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation, 2020, 141(20): 1648-1655.
25.	Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol, 2016, 1(3): 274-281.
26.	Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J, 2020, 41(19): 1798-1800.
27.	張鳳艷, 喬英, 張輝. 新型冠狀病毒肺炎的臨床及CT表現研究進展. 山西醫科大學學報, 2020, 56(5): 466-469.
28.	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
29.	Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 2020, 116(10): 1666-1687.
30.	叢超, 郭義山, 王東. 病毒性心肌炎發病機制的研究進展. 醫學綜述, 2020, 41(2): 144-147.
31.	Wang M, Zhang W, Zhou Y, et al. Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med, 2014, 7(6): 1721-1727.
32.	Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263.
33.	徐敏. 地震災難對軍隊醫護人員應急救援時心理健康的影響. 中國實用護理雜志, 2018, 34(17): 1314-1316.
34.	Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology, 2020, 160(3): 261-268.
35.	Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol, 2020, 92(11): 2283-2285.
36.	易春峰, 張帆, 楊力, 等. 新型冠狀病毒肺炎患者心肌損傷與炎癥相關性分析. 實用醫學雜志, 2020, 36(23): 3174-3178.
37.	Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm, 2020, 17(9): 1463-1471.
38.	張競文, 胡欣, 金鵬飛. 新型冠狀病毒引起的細胞因子風暴及其藥物治療. 中國藥學雜志, 2020, 55(5): 333-336.
39.	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol, 2012, 86(11): 6055-6066.
40.	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virusinduced viral pneumonia in the rhesus macaque. Virol, 2012, 86(11): 6055-6066.
41.	吳彪, 王春友. SIRS患者炎癥因子變化與病情相關性的研究. 中國現代普通外科進展, 2011, 14(6): 501-502.
42.	肖穎彬. 加強新冠肺炎對心血管系統損害的研究. 第三軍醫大學學報, 2021, 43(3): 183-187.
43.	Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 17(5): 259-260.
44.	Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun, 2020, 11(1): 5859.
45.	Li D, Chen Y, Jia Y, et al. SARS-CoV-2-induced immune dysregulation and myocardial injury risk in China: Insights from the ERS-COVID-19 study. Circ Res, 2020, 127(3): 397-399.
46.	Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184(3): 775-791.
47.	Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth, 2014, 58(5): 515-523.
48.	Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49.	Zheng Y, Zhang Y, Chi H, et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: A retrospective study. Clin Chem Lab Med, 2020, 58(7): 1106-1115.
50.	Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta, 2020, 506: 145-148.
51.	王曦, 安松濤, 李文博, 等. 新型冠狀病毒對循環系統影響的研究進展. 中華全科醫學, 2021, 19(2): 293-297.
52.	Mahenthiran AK, Mahenthiran AK, Mahenthiran J. Cardiovascular system and COVID-19: Manifestations and therapeutics. Rev Cardiovasc Med, 2020, 21(3): 399-409.
53.	王從容, 徐霞, 陳雅慧. 抗病毒藥物在新型冠狀病毒肺炎治療中的合理使用與藥學監護. 中國醫院藥學雜志, 2020, 40(10): 1693-2286.
54.	劉海淑. 干擾素在心血管方面的研究及臨床應用. 實用心腦肺血管病雜志, 2005, 13(2): 116-118.
55.	付琦, 馬秀云, 徐艷麗. 利巴韋林治療SARS患者致心率減慢的病例對照研究. 藥物不良反應雜志, 2004, 6(3): 154-156.
56.	龐文淵, 王喬宇, 趙志剛. 阿比多爾治療病毒性疾病的應用及評估. 中國藥物警戒, 2020, 17(6): 321-325, 337.
57.	郭棟, 郭萬剛, 劉鵬云, 等. 新型冠狀病毒感染的心臟表現. 心臟雜志, 2020, 32(1): 75-77.
58.	張勁農. 武漢協和醫院處置2019新型冠狀病毒感染策略及說明. URL: https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q. Accessed on 2020-01-23.
59.	新冠肺炎診療方案治療藥物信息匯編 (第1版). 中南藥學, 2020, 18(3): 345-358.
60.	Kunal S, Gupta K, Sharma SM, et al. Cardiovascular system and COVID-19: Perspectives from a developing country. Monaldi Arch Chest Dis, 2020, 90(2).
61.	Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2): 145-151.
62.	Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly, 2020, 2(8): 113-22.
63.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis, 2020, 20(6): 630-631.
64.	Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep, 2020, 69(24): 759-765.
65.	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
66.	Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N Engl J Med, 2020, 382(25): 2431-2440.
67.	Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens, 2020, 38(5): 781-782.
68.	Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med, 2020, 382(17): 1653-1659.
69.	Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med, 2020, 382(25): e102.
70.	Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med, 2020, 382(25): 2441-2448.
71.	張晨陽, 邵冬雪, 鄭曦, 等. ACE2與新型冠狀病毒肺炎的心腎損傷. 實用藥物與臨床, 2020, 23(10): 944-951.
72.	卜軍, 陳茂, 程曉曙, 等. 新型冠狀病毒肺炎防控形勢下急性心肌梗死診治流程和路徑的中國專家共識(第1版). 南方醫科大學學報, 2020, 40(2): 147-151.
73.	Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64(24): e139-e228.
74.	Key questions on COVID-19 and cardiovascular disease. Am Coll Cardiol, 2020-4-30.
75.	李美瑜, 呂明芳, 李翠芝, 等. 不同臨床分型新型冠狀病毒肺炎患者的心臟表現特征. 廣東醫學, 2020, 41(8): 797-800.
76.	蔡金原. 血管緊張素轉化酶2在新型冠狀病毒肺炎中的作用研究進展. 醫學研究生學報, 2021, 34(1): 107-112.
77.	Cox CE. Rivaroxaban may yet protect after a hospital dtay: MARINER. TCTMD—Cardiovascular Research Foundation. 2020-6-25.
78.	Wang J, Xu H, Yang X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis, 2017, 21(1): 12-18.
79.	Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA, 2015, 313(3): 264-274.
80.	Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet, 2020, 395(10239): 1771-1778.

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet, 2020, 395(10224): 565-574.
3. 劉欣, 叢曉東, 李平. 探討新型冠狀病毒對心血管系統的影響. 山東中醫藥大學學報, 2020 , 44(6): 462-546.
4. World Health Organization. SARS-CoV-2 variant—United Kingdom of Great Britain and Northern Ireland. 2020-12-21.
5. SARS-CoV-2 variants. World Health Organization. 2020-12-31.
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13): 1239-1242.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
8. 戴海龍, 馮曉嵐, 周旭, 等. 新型冠狀病毒肺炎對心血管的影響. 心肺血管病雜志, 2021, 39(6): 635-647, 641.
9. 張梅, 李闖. 新型冠狀病毒肺炎與心血管疾病. 武警醫學, 2020, 31(2): 93-96.
10. 倪國華, 李昆, 袁瓊. 新型冠狀病毒肺炎合并心血管疾病患者使用抗病毒藥物的藥學監護. 實用醫學雜志, 2020, 36(6): 3169-3173.
11. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5): 531-538.
12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
14. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.
15. Li D, Chen Y, Liu H, et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: Insights from ERS-COVID-19 study. Signal Transduct Target Ther, 2020, 5(1): 62.
16. 國家衛生健康委辦公廳國家中醫藥管理局辦公室. 關于印發新型冠狀病毒肺炎診療方案(試行第八版)的通知. 江蘇中醫藥, 2020, 52(9): 封2, 前插1-前插4.
17. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest, 2009, 39(7): 618-625.
18. 李發久, 朱紫陽, 陳實, 等. 新型冠狀病毒肺炎相關心肌損傷的臨床觀察. 第二軍醫大學學報, 2020, 42(5): 698-703.
19. 姜淑芳, 袁本敏, 韓志武. 新型冠狀病毒感染與心血管疾病. 青島大學學報(醫學版), 2020, 57(1): 156-158.
20. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
21. Guo J, Huang Z, Lin L, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc, 2020, 9(7): e016219.
22. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol, 2020, 75(18): 2352-2371.
23. Prasad A, Panhwar S, Hendel RC, et al. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J, 2020, 226: 174-187.
24. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation, 2020, 141(20): 1648-1655.
25. Nguyen JL, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol, 2016, 1(3): 274-281.
26. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J, 2020, 41(19): 1798-1800.
27. 張鳳艷, 喬英, 張輝. 新型冠狀病毒肺炎的臨床及CT表現研究進展. 山西醫科大學學報, 2020, 56(5): 466-469.
28. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
29. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 2020, 116(10): 1666-1687.
30. 叢超, 郭義山, 王東. 病毒性心肌炎發病機制的研究進展. 醫學綜述, 2020, 41(2): 144-147.
31. Wang M, Zhang W, Zhou Y, et al. Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med, 2014, 7(6): 1721-1727.
32. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263.
33. 徐敏. 地震災難對軍隊醫護人員應急救援時心理健康的影響. 中國實用護理雜志, 2018, 34(17): 1314-1316.
34. Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology, 2020, 160(3): 261-268.
35. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol, 2020, 92(11): 2283-2285.
36. 易春峰, 張帆, 楊力, 等. 新型冠狀病毒肺炎患者心肌損傷與炎癥相關性分析. 實用醫學雜志, 2020, 36(23): 3174-3178.
37. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm, 2020, 17(9): 1463-1471.
38. 張競文, 胡欣, 金鵬飛. 新型冠狀病毒引起的細胞因子風暴及其藥物治療. 中國藥學雜志, 2020, 55(5): 333-336.
39. Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol, 2012, 86(11): 6055-6066.
40. Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virusinduced viral pneumonia in the rhesus macaque. Virol, 2012, 86(11): 6055-6066.
41. 吳彪, 王春友. SIRS患者炎癥因子變化與病情相關性的研究. 中國現代普通外科進展, 2011, 14(6): 501-502.
42. 肖穎彬. 加強新冠肺炎對心血管系統損害的研究. 第三軍醫大學學報, 2021, 43(3): 183-187.
43. Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 17(5): 259-260.
44. Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun, 2020, 11(1): 5859.
45. Li D, Chen Y, Jia Y, et al. SARS-CoV-2-induced immune dysregulation and myocardial injury risk in China: Insights from the ERS-COVID-19 study. Circ Res, 2020, 127(3): 397-399.
46. Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184(3): 775-791.
47. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth, 2014, 58(5): 515-523.
48. Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49. Zheng Y, Zhang Y, Chi H, et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: A retrospective study. Clin Chem Lab Med, 2020, 58(7): 1106-1115.
50. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta, 2020, 506: 145-148.
51. 王曦, 安松濤, 李文博, 等. 新型冠狀病毒對循環系統影響的研究進展. 中華全科醫學, 2021, 19(2): 293-297.
52. Mahenthiran AK, Mahenthiran AK, Mahenthiran J. Cardiovascular system and COVID-19: Manifestations and therapeutics. Rev Cardiovasc Med, 2020, 21(3): 399-409.
53. 王從容, 徐霞, 陳雅慧. 抗病毒藥物在新型冠狀病毒肺炎治療中的合理使用與藥學監護. 中國醫院藥學雜志, 2020, 40(10): 1693-2286.
54. 劉海淑. 干擾素在心血管方面的研究及臨床應用. 實用心腦肺血管病雜志, 2005, 13(2): 116-118.
55. 付琦, 馬秀云, 徐艷麗. 利巴韋林治療SARS患者致心率減慢的病例對照研究. 藥物不良反應雜志, 2004, 6(3): 154-156.
56. 龐文淵, 王喬宇, 趙志剛. 阿比多爾治療病毒性疾病的應用及評估. 中國藥物警戒, 2020, 17(6): 321-325, 337.
57. 郭棟, 郭萬剛, 劉鵬云, 等. 新型冠狀病毒感染的心臟表現. 心臟雜志, 2020, 32(1): 75-77.
58. 張勁農. 武漢協和醫院處置2019新型冠狀病毒感染策略及說明. URL: https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q. Accessed on 2020-01-23.
59. 新冠肺炎診療方案治療藥物信息匯編 (第1版). 中南藥學, 2020, 18(3): 345-358.
60. Kunal S, Gupta K, Sharma SM, et al. Cardiovascular system and COVID-19: Perspectives from a developing country. Monaldi Arch Chest Dis, 2020, 90(2).
61. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020, 41(2): 145-151.
62. Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly, 2020, 2(8): 113-22.
63. Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis, 2020, 20(6): 630-631.
64. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep, 2020, 69(24): 759-765.
65. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271.
66. Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N Engl J Med, 2020, 382(25): 2431-2440.
67. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens, 2020, 38(5): 781-782.
68. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med, 2020, 382(17): 1653-1659.
69. Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med, 2020, 382(25): e102.
70. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med, 2020, 382(25): 2441-2448.
71. 張晨陽, 邵冬雪, 鄭曦, 等. ACE2與新型冠狀病毒肺炎的心腎損傷. 實用藥物與臨床, 2020, 23(10): 944-951.
72. 卜軍, 陳茂, 程曉曙, 等. 新型冠狀病毒肺炎防控形勢下急性心肌梗死診治流程和路徑的中國專家共識(第1版). 南方醫科大學學報, 2020, 40(2): 147-151.
73. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64(24): e139-e228.
74. Key questions on COVID-19 and cardiovascular disease. Am Coll Cardiol, 2020-4-30.
75. 李美瑜, 呂明芳, 李翠芝, 等. 不同臨床分型新型冠狀病毒肺炎患者的心臟表現特征. 廣東醫學, 2020, 41(8): 797-800.
76. 蔡金原. 血管緊張素轉化酶2在新型冠狀病毒肺炎中的作用研究進展. 醫學研究生學報, 2021, 34(1): 107-112.
77. Cox CE. Rivaroxaban may yet protect after a hospital dtay: MARINER. TCTMD—Cardiovascular Research Foundation. 2020-6-25.
78. Wang J, Xu H, Yang X, et al. Cardiac complications associated with the influenza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis, 2017, 21(1): 12-18.
79. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA, 2015, 313(3): 264-274.
80. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet, 2020, 395(10239): 1771-1778.

Previous Article
Progress in diagnosis and treatment of brain metastasis from colorectal cancer
Next Article
Research status of relationship between hepatitis B virus genotypes and hepatocarcinogenesis

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progess in effect of novel coronavirus on cardiovascular system

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content